Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | SBT6050 |
Trade Name | |
Synonyms | SBT-6050|SBT 6050|ImmunoTAC SBT6050|HER2-directed TLR8 Agonist SBT6050 |
Drug Descriptions |
SBT6050 comprises a TLR8 (CD288) agonist linked to an Erbb2 (Her2) monoclonal antibody, which may lead to activation of TLR8 expressing myeloid cells in the context of Erbb2 (Her2)-expressing tumors, potentially resulting in increased anti-tumor immune response (Cancer Res 2020;80(16 Suppl):Abstract nr 4537). |
DrugClasses | HER2 (ERBB2) Antibody 76 TLR8 Agonist 9 |
CAS Registry Number | NA |
NCIT ID | C174010 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Capecitabine + SBT6050 + Trastuzumab + Tucatinib | Capecitabine SBT6050 Trastuzumab Tucatinib | 0 | 1 |
Capecitabine + SBT6050 + Trastuzumab deruxtecan + Tucatinib | Capecitabine SBT6050 Trastuzumab deruxtecan Tucatinib | 0 | 0 |
Cemiplimab + SBT6050 | Cemiplimab SBT6050 | 0 | 1 |
Pembrolizumab + SBT6050 | Pembrolizumab SBT6050 | 0 | 1 |
SBT6050 | SBT6050 | 0 | 1 |
SBT6050 + Trastuzumab + Tucatinib | SBT6050 Trastuzumab Tucatinib | 0 | 1 |
SBT6050 + Trastuzumab deruxtecan | SBT6050 Trastuzumab deruxtecan | 0 | 1 |